Cargando…
Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts
BACKGROUND: In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (MDMX/MDM4) are frequently overexpressed in wild-type p5...
Autores principales: | Lenos, Kristiaan, de Lange, Job, Teunisse, Amina FAS, Lodder, Kirsten, Verlaan-de Vries, Matty, Wiercinska, Eliza, van der Burg, Marja JM, Szuhai, Karoly, Jochemsen, Aart G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179748/ https://www.ncbi.nlm.nih.gov/pubmed/21910853 http://dx.doi.org/10.1186/1476-4598-10-111 |
Ejemplares similares
-
Functions of MDMX in the Modulation of the p53-Response
por: Lenos, Kristiaan, et al.
Publicado: (2011) -
MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
por: Heijkants, Renier C., et al.
Publicado: (2022) -
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies
por: Heijkants, R. C., et al.
Publicado: (2018) -
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
por: Glinkina, Kseniya A., et al.
Publicado: (2023) -
Targeting Mdmx to treat breast cancers with wild-type p53
por: Haupt, S, et al.
Publicado: (2015)